Spero Therapeutics (SPRO) Projected to Post Earnings on Wednesday

Spero Therapeutics (NASDAQ:SPRO) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect Spero Therapeutics to post earnings of ($0.44) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30. Spero Therapeutics had a net margin of 3.30% and a return on equity of 4.03%. The business had revenue of $5.87 million during the quarter, compared to analysts’ expectations of $11.00 million. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Stock Performance

Shares of Spero Therapeutics stock opened at $0.65 on Monday. Spero Therapeutics has a 52-week low of $0.51 and a 52-week high of $1.60. The stock has a market capitalization of $36.40 million, a price-to-earnings ratio of 9.30 and a beta of 0.23. The company has a fifty day moving average of $0.69 and a 200-day moving average of $0.89.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Spero Therapeutics in a research note on Thursday, January 30th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.